Alexander Höllein
YOU?
Author Swipe
Venetoclax combined with five days of azacitidine for the treatment of previously untreated Acute Myeloid Leukemia (AML): Initial results of the prospective venaza-5S trial Open
Background: The combination of Azacitidine (AZA) and Venetoclax (VEN) has become the standard of care frontline treatment for AML patients who are ineligible for intensive treatment due to advanced age or comorbidities, based on the result…
View article: VINCENT: A randomized-controlled trial evaluating venetoclax plus azacitidine versus intensive chemotherapy in patients with newly diagnosed, NPM1-mutated AML
VINCENT: A randomized-controlled trial evaluating venetoclax plus azacitidine versus intensive chemotherapy in patients with newly diagnosed, NPM1-mutated AML Open
For younger, medically fit patients with NPM1 -mutated, FLT3 -wildtype acute myeloid leukemia (AML) intensive chemotherapy represents standard of care (SOC), with complete remission (CR) rates observed in up to 85% of patients and 5-year o…
View article: Indeterminate and oncogenic potential: CHIP vs CHOP mutations in AML with NPM1 alteration
Indeterminate and oncogenic potential: CHIP vs CHOP mutations in AML with NPM1 alteration Open
In AML patients, recurrent mutations were shown to persist in remission, however, only some have a prognostic value and persistent mutations might therefore reflect a re-established premalignant state or truly active disease causing relaps…
Knowledge transfer to enhance the performance of deep learning models for automated classification of B-cell neoplasms Open
Multi-parameter flow cytometry (MFC) is a cornerstone in clinical decision making for hematological disorders such as leukemia or lymphoma. MFC data analysis requires trained experts to manually gate cell populations of interest, which is …
Characteristics and outcomes of patients with cancer and COVID-19: results from a cohort study Open
The COVID-19 pandemic has transformed clinical care around the world with elective procedures being postponed and regular medical care being compromised by patient isolation and repeated testing. D...
Hematologist‐Level Classification of Mature B‐Cell Neoplasm Using Deep Learning on Multiparameter Flow Cytometry Data Open
The wealth of information captured by multiparameter flow cytometry (MFC) can be analyzed by recent methods of computer vision when represented as a single image file. We therefore transformed MFC raw data into a multicolor 2D image by a s…
Hematologist-level classification of mature B-cell neoplasm using deep learning on multiparameter flow cytometry data Open
The wealth of information captured by multiparameter flow cytometry (MFC) can be analyzed by recent methods of computer vision when represented as a single image file. We therefore transformed MFC raw data into a multicolor 2D image by a s…
Issue Information Open
The many roles of tranexamic acid: An overview of the clinical indications for TXA in medical and surgical patients
Inhibition of PLK1 by capped‐dose volasertib exerts substantial efficacy in MDS and sAML while sparing healthy haematopoiesis Open
Introduction Targeting the cell cycle machinery represents a rational therapeutic approach in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML). Despite substantial response rates, clinical use of the PLK inhibito…
Complement and inflammasome overactivation mediates paroxysmal nocturnal hemoglobinuria with autoinflammation Open
Patients with paroxysmal nocturnal hemoglobinuria (PNH) have a clonal population of blood cells deficient in glycosylphosphatidylinositol-anchored (GPI-anchored) proteins, resulting from a mutation in the X-linked gene PIGA. Here we report…
View article: Molecular characterization of AML with <i>RUNX1‐RUNX1T1</i> at diagnosis and relapse reveals net loss of co‐mutations
Molecular characterization of AML with <i>RUNX1‐RUNX1T1</i> at diagnosis and relapse reveals net loss of co‐mutations Open
Supplemental Digital Content is available in the text
View article: NPM1 mutated AML can relapse with wild-type NPM1: persistent clonal hematopoiesis can drive relapse
NPM1 mutated AML can relapse with wild-type NPM1: persistent clonal hematopoiesis can drive relapse Open
Acute myeloid leukemia (AML) with NPM1 mutation (NPM1mut) defines a World Health Organization entity. Absence of minimal residual disease (MRD) following induction chemotherapy is associated with an excellent prognosis. Data are conflictin…
CDK6 Antagonizes p53-Induced Responses during Tumorigenesis Open
Tumor formation is a multistep process during which cells acquire genetic and epigenetic changes until they reach a fully transformed state. We show that CDK6 contributes to tumor formation by regulating transcriptional responses in a stag…